| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2022 | 8.11% | Morgan Stanley | $13 → $14 | Maintains | Underweight |
| 08/08/2022 | 0.39% | Morgan Stanley | $12 → $13 | Maintains | Underweight |
| 07/20/2022 | 23.55% | Goldman Sachs | → $16 | Initiates Coverage On | → Neutral |
| 07/15/2022 | -7.34% | Morgan Stanley | $13 → $12 | Maintains | Underweight |
| 04/12/2022 | 0.39% | Morgan Stanley | $12 → $13 | Maintains | Underweight |
| 02/23/2022 | -7.34% | Morgan Stanley | $10 → $12 | Maintains | Underweight |
| 02/11/2022 | 116.22% | EF Hutton | → $28 | Initiates Coverage On | → Buy |
| 11/11/2020 | -22.78% | Morgan Stanley | $8 → $10 | Maintains | Underweight |
| 06/25/2018 | — | Stifel | Terminates Coverage On | Hold → Hold | |
| 04/27/2018 | 23.55% | Stifel | $17 → $16 | Maintains | Hold |
| 11/20/2017 | 0.39% | Deutsche Bank | → $13 | Initiates Coverage On | → Hold |
Innoviva Questions & Answers
The latest price target for Innoviva (NASDAQ: INVA) was reported by Morgan Stanley on October 13, 2022. The analyst firm set a price target for $14.00 expecting INVA to rise to within 12 months (a possible 8.11% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Innoviva (NASDAQ: INVA) was provided by Morgan Stanley, and Innoviva maintained their underweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innoviva, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innoviva was filed on October 13, 2022 so you should expect the next rating to be made available sometime around October 13, 2023.
While ratings are subjective and will change, the latest Innoviva (INVA) rating was a maintained with a price target of $13.00 to $14.00. The current price Innoviva (INVA) is trading at is $12.95, which is out of the analyst's predicted range.